Respiratory infections remain among the most common — and most serious — health challenges worldwide. From influenza and pneumonia to COVID-19 and other acute illnesses, these diseases are a leading cause of hospitalisation and death, placing a sustained burden on health systems.
At the same time, they sit at the centre of one of medicine’s most pressing dilemmas: how to treat effectively when the cause of infection is not immediately clear. In many cases, uncertainty leads to antibiotics being prescribed as a precaution, despite most respiratory illnesses being viral. That practice continues to accelerate the global spread of antimicrobial resistance (AMR).
The antibiotic dilemma
According to the World Health Organisation, antimicrobial resistance is now responsible for nearly 5 million deaths a year, and respiratory infections are one of its major drivers. In busy clinics and emergency rooms, doctors are under pressure to treat quickly. Without rapid, reliable tools to determine whether an infection is bacterial, the safest immediate option can seem to be prescribing antibiotics.
The problem is that each unnecessary course of antibiotics adds to the selective pressure that breeds resistant “superbugs.” Left unchecked, AMR threatens to roll back decades of progress in modern medicine, making common infections harder to treat and routine procedures more dangerous.
Innovation on two fronts
Researchers and biotech companies are responding to this challenge on two main fronts: diagnostics and therapeutics.
- Diagnostics aim to give clinicians faster, clearer answers. Rapid point-of-care tests that distinguish between bacterial and viral infections can prevent inappropriate prescribing and allow antibiotics to be targeted only when truly needed.
- Therapeutics include both next-generation antibiotics and novel anti-infectives designed to outsmart resistance. These range from synthetic compounds that attack bacteria in new ways, to biologics and phage-based therapies that harness natural mechanisms to kill pathogens.
Together, these innovations could shift the trajectory of how respiratory infections are managed — improving patient outcomes while slowing the spread of resistance.
On the ASX, Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has been working on a promising diagnostic solution, for example. Its FebriDx test uses a small finger-stick blood sample to detect host-response proteins that help differentiate between bacterial and viral respiratory infections in minutes.
Lumos has submitted a CLIA waiver application to the US Food and Drug Administration, a key step that would allow FebriDx to be used in doctor’s offices, urgent care centres and other low-complexity settings. Backed by funding from the US Biomedical Advanced Research and Development Authority (BARDA), the company hopes the test will help reduce unnecessary antibiotic prescribing — directly addressing one of the most pressing AMR challenges.
Read more: Lumos Diagnostics submits CLIA waiver application for FebriDx
Toward a more sustainable response
The broader lesson is that fighting respiratory infections requires a multi-layered approach. Vaccines remain essential in reducing incidence and severity. Novel therapeutics will be needed to replace or supplement older antibiotics as resistance grows. And diagnostics like Lumos’ FebriDx can help ensure the right treatments are used at the right time.
Respiratory infections are not going away — if anything, the experience of COVID-19 has underscored how disruptive they can be. But by combining prevention, precision diagnostics and innovative therapies, biotech companies are helping to ensure that doctors have more than just antibiotics at their disposal.
The challenge is immense, but so is the potential. Each step toward smarter, faster and more targeted responses to respiratory disease is a step away from a world where superbugs call the shots.